Show simple item record

dc.contributor.authorNieder, Carsten
dc.contributor.authorMannsåker, Bård
dc.contributor.authorDalhaug, Astrid
dc.contributor.authorPawinski, Adam
dc.contributor.authorHaukland, Ellinor Christin
dc.date.accessioned2018-07-26T12:59:46Z
dc.date.available2018-07-26T12:59:46Z
dc.date.issued2017-04-26
dc.description.abstractThe purpose of the present retrospective study was to investigate whether a score reflecting systemic inflammatory processes [the Glasgow Prognostic Score (GPS)] provides relevant information for radiation oncologists. GPS is a three‑tiered score [0: normal C-reactive protein (CRP) and albumin; 1: one abnormal result; 2: increased CRP and low albumin]. Correlations between disease type and extent, resource utilization, survival and GPS were analyzed in 703 patients. In the subgroup with GPS 2, significantly higher rates of lung, adrenal gland and liver metastases were observed. An increasing GPS score was associated with a higher likelihood of anemia, leukocytosis and thrombocytosis. Comparable findings were made regarding utilization of palliative care resources, need for blood transfusion and intravenous administration of antibiotics. Compared with GPS 0 or 1, more patients with GPS 2 did not complete their prescribed course of radiotherapy. One-third of patients with GPS 2 received treatment during the final month of life. Multivariate analysis demonstrated that GPS was a significant prognostic factor for overall survival (median, 479, 136, and 61 days, for GPS 0, 1 and 2, respectively). In patients with GPS 2 and additional leukocytosis, the median survival was 38 days. In conclusion, GPS provides important prognostic information. This biomarker-based score may be considered for deciding fractionation, and should be validated further.en_US
dc.descriptionThe following article: Nieder, C., Mannsåker, B., Dalhaug, A., Pawinski, A. & Haukland, E. (2017). The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy. Molecular and clinical oncology, 6, 811-816. https://doi.org/10.3892/mco.2017.1228 was published 26 April 2017 in <i>Molecular and clinical oncology</i>. Source at <a href=https://doi.org/10.3892/mco.2017.1228> https://doi.org/10.3892/mco.2017.1228</a>.en_US
dc.identifier.cristinIDFRIDAID 1545355
dc.identifier.doi10.3892/mco.2017.1228
dc.identifier.issn2049-9450
dc.identifier.issn2049-9469
dc.identifier.urihttps://hdl.handle.net/10037/13287
dc.language.isoengen_US
dc.publisherSpandidos Publicationsen_US
dc.relation.journalMolecular and clinical oncology
dc.rights.accessRightsopenAccessen_US
dc.subjectradiation therapyen_US
dc.subjectpalliative radiotherapyen_US
dc.subjectbiomarkers, prognostic scoreen_US
dc.subjectalbuminen_US
dc.subjectC-reactive proteinen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.titleThe Glasgow prognostic score: Useful information when prescribing palliative radiotherapyen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record